Clinical TrialsSearch results
Number of results: 904
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- 39-301: Special Drug Use-Results Survey of DEMSER
- Pheochromocytoma
- Kuro Toshihiko
- 2024-11-08
Other
- Changes in depressive symptoms during the COVID-19 pandemic and coping among people with mental disorders.
- Depressive symptoms and coping
- Fukase Yuko
- 2024-10-28
Recruiting
- Rhythm jump training intervention for middle school soccer players
- Non-malignant tumors
- Takahira Naonobu
- 2024-10-28
Recruiting
- Examining the impact of cultural prescriptions of art on self-compassion in psychiatric outpatients with social communication and interpersonal difficulties.
- Outpatients with developmental or personality characteristics
- Miyazaki Tomoyuki
- 2024-10-21
Recruiting
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
- Plaque Psoriasis
- Shikamura Mitsuhiro
- 2024-10-18
Recruiting
- Theta burst stimulation for unilatelal spatial neglect
- Stroke
- Mizuno Katsuhiro
- 2024-10-10
Not yet recruiting
- JASPER study-MTX tapering
- Rheumatoid arthritis
- Yamaoka Kunihiro
- 2024-10-09
Recruiting
- A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion - Master Protocol
AMG 193 in Combination with mFOLFIRINOX or with Gemcitabine and Nab-paclitaxel in Subjects with Advanced PDAC with Homozygous MTAP-deletion (Subprotocol B)
- Pancreatic Cancers
- Iizumi Sakura
- 2024-10-07
Recruiting
- Clinical efficacy and safety of BRAF/MEK inhibitors for anaplastic thyroid cancer; An observational study of ATC Research Consortium of Japan.
- Anaplastic thyroid cancer
- Suganuma Nobuyasu
- 2024-10-03
Completed
- Post-marketing observational study on the efficacy and safety of Neuroguidewire for the treatment of istroke and aneurysm
- acute ischemic stroke and brain aneurysm
- Morimoto Masafumi
- 2024-10-03